| Document |
Document Title |
|
WO/2023/011358A1 |
Disclosed are novel pharmaceutical salts and polymorphic forms of (R) -N- (5- ( (4- ( (5-chloro-4-fluoro-2- (2-hydroxypropan-2-yl) phenyl) amino) pyrimidin-2-yl) amino) -2- (3- (dimethylamino) pyrrolidin-1-yl) -4-methoxyphenyl) acrylamid...
|
|
WO/2023/014022A1 |
The present invention relates to a pyrimidine derivative, a method for preparing same, and a pharmaceutical composition for preventing or treating cancer comprising same as an active ingredient. The pyrimidine derivative of the present i...
|
|
WO/2023/006986A1 |
The present invention relates to a new process for preparing and purifying N-[(1,3-dicyclohexyl-2,4,6-trioxohexahydropyrimidin-5-yl)car
bonyl]glycine, an agent developed for the treatment of anemia, and intermediates thereof.
|
|
WO/2023/005280A1 |
Disclosed in the present invention are preparation and application of an aminopyrimidine derivative selectively targeting CDK9. Also disclosed in the present invention are a preparation method for the compound and an application of the c...
|
|
WO/2023/003468A1 |
The invention relates to the field of medicinal chemistry and pharmacology, specifically to novel inhibitors of histone deacetylase (HDAC), and to compositions, methods of making, and using them, for instance in the treatment of chronic ...
|
|
WO/2023/286719A1 |
The present invention addresses the problem of providing: an industrially advantageous method for producing a uracil compound, which is a production intermediate of a 2,6-dioxo-3,6-dihydropyrimidine compound; and a ureidomethylene compou...
|
|
WO/2023/283743A1 |
The present invention provides compounds of formula (I): NR1R2SOOYR3 (I) or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), and use of the ...
|
|
WO/2023/285787A1 |
A process for preparing a compound of formula I, or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula I.
|
|
WO/2023/285222A1 |
The present invention relates to phenyluracils of formula (I) or their agriculturally acceptable salts or derivatives, wherein the variables are defined accord-ing to the description, compositions comprising them and their use as herbici...
|
|
WO/2023/285788A1 |
A process for preparing a compound of formula (I), or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula (I).
|
|
WO/2023/280237A1 |
A synthesis and an application of a phosphatase degrader, belonging to the field of chemical medicine. The phosphatase degrader is a compound represented by formula I, or a salt thereof, or a deuterated compound thereof, or a stereoisome...
|
|
WO/2023/278977A1 |
Described herein are compounds methods for reducing the amount of rest compressor 1 (RCOR1, also known as CoREST1), lysine-specific histone demethylase 1A (LSD1, also known as KDM1A), histone deacetylase 1 (HDAC1), histone deacetylase 2 ...
|
|
WO/2023/277594A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
|
WO/2023/277289A1 |
The present application provides: a heterocyclic compound; and an organic light-emitting device which comprises an organic layer containing the heterocyclic compound.
|
|
WO/2022/271677A1 |
The application relates to diacylglycerol kinase modulating quinazolin-2-one derivatives of the general Formula (I), and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV ...
|
|
WO/2022/269049A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, A, L1, L2, Y and Z are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formu...
|
|
WO/2022/270987A1 |
The present invention relates to a novel compound that induces selective degradation of AURKA, and specifically provides a bifunctional compound in which an AURKA binding moiety and an E3 ubiquitin ligase binding moiety are linked by a c...
|
|
WO/2022/263829A1 |
The invention relates to compounds or salts of Formula (I-a), Formula (I-b), Formula (I-c), Formula (I-d), Formula (II) and pharmaceutical compositions containing these compounds. The compounds may be inducers of α1-antitrypsin (A1AT), ...
|
|
WO/2022/262686A1 |
Disclosed are novel compounds which are KRAS G12D inhibitors, their synthesis and their use for treating diseases or conditions, such as cancer, and in particular for inhibiting the activity of KRAS G12D, pharmaceutical compositions comp...
|
|
WO/2022/266427A1 |
The present disclosure relates to compounds of Formula (I) and pharmaceutically acceptable salts and stereoisomers thereof, useful in the treatment of cancers associated with ErbB oncogenic activity, including methods of preparing the co...
|
|
WO/2022/264826A1 |
The compound is represented by formula (1) below.
|
|
WO/2022/261770A1 |
The present invention relates to a combination comprising a neurotensin receptor binding compound and FOLFIRINOX for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.
|
|
WO/2022/264827A1 |
A compound represented by formula (1).
|
|
WO/2022/263899A1 |
The present disclosure relates to a manufacturing process for daprodustat in which the level of an acyl impurity of Formula (II) is kept below 0.15% w/w in isolated daprodustat drug substance. Immediate release formulations of daprodusta...
|
|
WO/2022/261250A1 |
The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer,...
|
|
WO/2022/234487A9 |
Of The Disclosure The present invention provides crystalline forms of 5-fluoro-4-imino-3-methyl-1-tosyl-3,4-dihydropyrimidin-2(1H)
-one, and uses and processes of preparation thereof. The present invention also provides combinations, mix...
|
|
WO/2022/257875A1 |
The present invention relates to a compound as represent by formula (I), a pharmaceutical composition comprising same, a preparation method therefor and the use thereof for treating neurodegenerative diseases.
|
|
WO/2022/260096A1 |
Provided is a photoelectric conversion element material that is for an imaging element and that contributes to production of a photoelectric conversion element that is for an imaging element and that exhibits excellent dark current and e...
|
|
WO/2022/256806A1 |
Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatmen...
|
|
WO/2022/253294A1 |
The present disclosure provides a pyridone compound having integrase inhibitory activity and a pharmaceutical use thereof. Specifically, the present disclosure provides a compound having a structure shown as formula I or a pharmaceutical...
|
|
WO/2022/254034A1 |
The present invention concerns a compound having the formula (I), wherein: R1 is selected from the group consisting of: H, F, (C1-C6)alkoxy, and halo(C1-C6)alkyl; and R2 is an optionally substituted heteroaryl group, as well as processes...
|
|
WO/2022/256075A1 |
Pyrimidine and Pyridine amine containing compounds are described herein that are enzyme p70S6K inhibitors useful in the treatment of S6K-dependent or S6K-mediated diseases and conditions, including but not limited to cancer, fibrotic met...
|
|
WO/2022/247770A1 |
A nitrogen-containing heterocyclic compound, a preparation method therefor and an application thereof. A nitrogen-containing heterocyclic compound represented by formula I, a pharmaceutically acceptable salt thereof, a stereoisomer there...
|
|
WO/2022/251647A1 |
This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical agents which function as inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral replicatio...
|
|
WO/2022/244765A1 |
[Problem] To provide a novel eye drop for suppressing myopia. [Solution] The above problem has been solved by using an eye drop containing bunazosin as an eye drop for suppressing myopia. This eye drop for suppressing myopia is effective...
|
|
WO/2022/241186A1 |
Disclosed herein are compositions and pharmaceutical formulations comprising a functionally selected β-arrestin-biased NTSR1 ligand (such as SBI-553 and SBI-810) and methods of using those compositions and pharmaceutical formulations fo...
|
|
WO/2022/238694A1 |
Compounds of formula (I) or formula (II) are disclosed: Wherein Y1, Y2, and Y3 are independently selected from C-R1 or N. Such compounds find use as antibiotics and antifungals.
|
|
WO/2022/240826A1 |
The present invention relates generally to compositions and methods for treating cancer, e.g. by using the compounds of formula (I). Provided herein are substituted bicyclic heteroaryl derivative compounds and pharmaceutical compositions...
|
|
WO/2022/237456A1 |
Disclosed is the use of a series of 4-arylaminoquinazoline hydroxamic acid compounds in the preparation of a drug for treating neuropathic pain diseases, and specifically, the use of a compound as represented by formula III-2, a tautomer...
|
|
WO/2022/236133A1 |
Provided herein are fatty acid amide (FAAH) cleavable prodrugs of thyromimetics and pharmaceutical compositions comprising these compounds with at least one pharmaceutically acceptable excipient further comprising a peripherally restrict...
|
|
WO/2022/228218A1 |
An application of a quinazoline compound and a pharmaceutical composition. The quinazoline compound is the quinazoline compound shown in formula A, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharma...
|
|
WO/2022/228577A1 |
The present invention provides a novel benzotropone derivative, and a preparation method therefor and an application thereof. The novel benzotropone derivative has a structure as represented by general formula (I) or formula (II), wherei...
|
|
WO/2022/232259A1 |
Provided herein are soluble adenylyl cyclase (sAC) inhibitors and uses thereof. In one aspect, provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, s...
|
|
WO/2022/232632A1 |
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodru...
|
|
WO/2022/226118A1 |
The invention encompasses novel dihydroquinoxalinone compounds with significantly improved water solubility and reduced toxicity to achieve higher therapeutic indexes and the treatment of cancer, virus infections, and inflammation using ...
|
|
WO/2022/223033A1 |
An SOS1 degrading agent and a preparation method therefor and an application thereof. Specifically, disclosed is a compound represented by formula I: S-L-E(I), wherein L is a linker chain, which connects S and E by means of covalent bond...
|
|
WO/2022/225866A1 |
The disclosure relates to quinazoline derivatives, pharmaceutical compositions, and therapeutic methods related thereto. In certain embodiments, this disclosure relates to compounds and methods of treating or preventing a Nox-related dis...
|
|
WO/2022/223034A1 |
An SOS1 degradation agent and a preparation method therefor and an application thereof. Specifically, disclosed is a compound of formula I: S-L-E(I), wherein L is a linking chain, which links S and E by means of covalent bonds; E is a sm...
|
|
WO/2022/223039A1 |
An SOS1 degrader, a preparation method therefor and an application thereof. Specifically, the present invention relates to a compound of formula I: S-L-E (I), wherein S is a small molecule compound capable of inhibiting the activity of a...
|
|
WO/2022/217364A1 |
A new class of antibiotics, namely, mercaptoacetophenone aminohydrazones, their analogues, their method of preparation, their salts, and their use in cases of bacterial infections, either alone or with other compounds.
|
